Injectable delivery system of 2-methoxyestradiol for breast cancer therapy using biodegradable thermosensitive poly(organophosphazene) hydrogel

Journal of Drug Targeting

Volumn 19, Issue 4, 2011, Pages 270-280

  Cho, Jung Kyo ^a,b   Hong, Ki Yun ^a   Park, Jung Won ^a,c   Yang, Han Kwang ^d   Song, Soo Chang ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

^c Korea University   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

2 methoxyestradiol; biodegradable; breast cancer; hydrogel; Injectable; poly(organophosphazene); thermosensitive

Indexed keywords

2 METHOXYESTRADIOL; ALPHA AMINO OMEGA METHOXY POLY(ETHYLENE GLYCOL); CD31 ANTIGEN; ISOLEUCINE ETHYL ESTER,ETHYL 2 (O GLYCYL)LACTATE; POLY(ORGANOPHOSPHAZENE); POLYMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CHEMICAL STRUCTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISPERSION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; FEMALE; HEAT SENSITIVITY; HUMAN; HUMAN CELL; HYDROGEL; HYDROPHOBICITY; IC 50; IMMUNOHISTOCHEMISTRY; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYNTHESIS; TUMOR VOLUME; VISCOMETRY;

ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG CARRIERS; ESTRADIOL; FEMALE; HUMANS; HYDROGELS; IMMUNOHISTOCHEMISTRY; MICE; NEOPLASMS, EXPERIMENTAL; ORGANOPHOSPHORUS COMPOUNDS; POLYMERS; RHEOLOGY; SOLUBILITY;

EID: 79953005259     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2010.499461     Document Type: Article

References (50)

1. Baumann MD, Kang CE, Stanwick JC, Wang Y, Kim H, Lapitsky Y, Shoichet MS. (2009). An injectable drug delivery platform for sustained combination therapy. J Control Release, 138, 205-213.
2. Bromberg L, Temchenko M. (1999). Self-assembly in aqueous solutions of poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide)-b-poly(vinyl alcohol). Langmuir, 15, 8633-8639.
3. Bryan N, Rhodes NP, Hunt JA. (2009). Derivation and performance of an entirely autologous injectable hydrogel delivery system for cell-based therapies. Biomaterials, 30, 180-188.
4. Burke PA, Swartz GM, Hanson AD, Chen B, Agoston GE, Shah J, Suwandi L, Fogler WE, Treston AM, Lavallee TM. (2005). 2-Methoxyestradiol analog 883 shows improved anti-tumor activity in vitro with increased survival and reduced tumor burden in vivo. AACR Meeting Abstracts, 1376-a.
5. Censi R, Vermonden T, van Steenbergen MJ, Deschout H, Braeckmans K, De Smedt SC, van Nostrum CF, di Martino P, Hennink WE. (2009). Photopolymerized thermosensitive hydrogels for tailorable difusion-controlled protein delivery. J Control Release, 140, 230-236.
6. Chun C, Lee SM, Kim CW, Hong KY, Kim SY, Yang HK, Song SC. (2009a). Doxorubicin-polyphosphazene conjugate hydrogels for locally controlled delivery of cancer therapeutics. Biomaterials, 30, 4752-4762.
7. Chun C, Lee SM, Kim SY, Yang HK, Song SC. (2009b). Termosensitive poly(organophosphazene)-paclitaxel conjugate gels for antitumor applications. Biomaterials, 30, 2349-2360.
8. Clemons M, Goss P. (2001). Estrogen and the risk of breast cancer. N Engl J Med, 344, 276-285. (Pubitemid 32108534)
9. Comolli N, Neuhuber B, Fischer I, Lowman A. (2009). In vitro analysis of PNIPAAm-PEG, a novel, injectable scafold for spinal cord repair. Acta Biomater, 5, 1046-1055.
10. Crommen J, Vandorpe J, Schacht E. (1993). Degradable polyphosphazenes for biomedical applications. J Controlled Release, 24, 167-180. (Pubitemid 23161329)
11. D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E. (1994). 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA, 91, 3964-3968. (Pubitemid 24139553)
12. Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D, Parr A, Nguyen D, Yang SX, Steinberg SM, Venitz J, Sparreboom A, Figg WD. (2006). Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ter, 5, 22-27. (Pubitemid 43234973)
13. Desai KG, Mallery SR, Schwendeman SP. (2008). Efect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(DL-lactide-co-glycolide) implants. Eur J Pharm Biopharm, 70, 187-198.
14. Edsall AB, Agoston GE, Treston AM, Plum SM, McClanahan RH, Lu TS, Song W, Cushman M. (2007). Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate. J Med Chem, 50, 6700-6705. (Pubitemid 350309107)
15. Elstad NL, Fowers KD. (2009). OncoGel (ReGel/paclitaxel)\clinical applications for a novel paclitaxel delivery system. Adv Drug Deliv Rev, 61, 785-794.
16. Fotsis T, Zhang Y Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L. (1994). Te endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature, 368, 237-239. (Pubitemid 24108838)
17. Greenstein JP, Winitz M. (1961). Amino Acid Methyl and Ethyl Esters Chemistry of the Amino Acids. New York: John Wiley & Son.
18. Guo DD, Xu CX, Quan JS, Song CK, Jin H, Kim DD, Choi YJ, Cho MH, Cho CS. (2009). Synergistic anti-tumor activity of paclitaxel-incorporated conjugated linoleic acid-coupled poloxamer thermosensitive hydrogel in vitro and in vivo. Biomaterials, 30, 4777-4785.
19. Guo X, Park H, Young S, Kretlow JD, van den Beucken JJ, Baggett LS, Tabata Y Kasper FK, Mikos AG, Jansen JA. (2010) Repair of osteochondral defects with biodegradable hydrogel composites encapsulating marrow mesenchymal stem cells in a rabbit model. Acta Biomaterialia, 6, 39-47.
20. Han SU, Kim HT, Seong DH, Kim YS, Park YS, Bang YJ, Yang HK, Kim SJ. (2004). Loss of the Smad3 expression increases susceptibility to tumorigenicity in human gastric cancer. Oncogene, 23, 1333-1341. (Pubitemid 38406829)
21. Han GZ, Liu ZJ, Shimoi K, Zhu BT. (2005). Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer. Cancer Res, 65, 387-393.
22. Howland RD, Mycek MJ. (2006). Pharmacokinetics. Pharmcology. Philadelphia: Lippincott Williams & Wilkins.
23. Kang GD, Cheon SH, Khang G, Song SC. (2006a). Termosensitive poly(organophosphazene) hydrogels for a controlled drug delivery. Eur J Pharm Biopharm, 63, 340-346. (Pubitemid 43776232)
24. Kang GD, Cheon SH, Song SC. (2006b). Controlled release of doxorubicin from thermosensitive poly(organophosphazene) hydrogels. Int J Pharm, 319, 29-36. (Pubitemid 44051797)
25. Kerbel R, Folkman J. (2002). Clinical translation of angiogenesis inhibitors. Nat Rev Cancer, 2, 727-739. (Pubitemid 37328908)
26. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. (1997). Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res, 57, 81-86. (Pubitemid 27021522)
27. Lee F, Chung JE, Kurisawa M. (2009a). An injectable hyaluronic acid-tyramine hydrogel system for protein delivery. J Control Release, 134, 186-193.
28. Lee J, Tan CY, Lee SK, Kim YH, Lee KY. (2009b). Controlled delivery of heat shock protein using an injectable microsphere/hydrogel combination system for the treatment of myocardial infarction. J Control Release, 137, 196-202.
29. Lee SM, Chun CJ, Heo JY Song S-C. (2009c) Injectable and thermosensitive poly(organophosphazene) hydrogels for a 5-fuorouracil delivery. J Appl Polym Sci, 113, 3831-3839.
30. Lei P, Padmashali RM, Andreadis ST (2009). Cell-controlled and spatially arrayed gene delivery from fbrin hydrogels. Biomaterials, 30, 3790-3799.
31. Lippert C, Seeger H, Mueck AO, Lippert TH. (2000). Te efects of A-ring and D-ring metabolites of estradiol on the proliferation of vascular endothelial cells. Life Sci, 67, 1653-1658. (Pubitemid 30663020)
32. Liu ZJ, Zhu BT (2004). Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells. J Steroid Biochem Mol Biol, 88, 265-275. (Pubitemid 38553758)
33. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P. (2003). 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell, 3, 363-375. (Pubitemid 38340305)
34. Namgung R, Nam S, Kim SK, Son S, Singha K, Kwon JS, Ahn Y, Jeong MH, Park IK, Garripelli VK, Jo S, Kim WJ. (2009). An acid-labile temperature-responsive sol-gel reversible polymer for enhanced gene delivery to the myocardium and skeletal muscle cells. Biomaterials, 30, 5225-5233.
35. Park K, Shalaby WSW, Park H. (1993). Physical Gels. Biodegradable Hydrogels for Drug Delivery. Pennsylvania: Technomic Publishing Company, Inc
36. Potta T, Chun C, Song SC. (2009). Chemically crosslinkable thermosensitive polyphosphazene gels as injectable materials for biomedical applications. Biomaterials, 30, 6178-6192.
37. Pribluda VS, Gubish ER Jr, Lavallee TM, Treston A, Swartz GM, Green SJ. (2000). 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev, 19, 173-179. (Pubitemid 32004707)
38. Pusztaszeri MP, Seelentag W, Bosman FT (2006). Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem, 54, 385-395.
39. Shapira-Schweitzer K, Habib M, Gepstein L, Seliktar D. (2009). A photopolymerizable hydrogel for 3-D culture of human embryonic stem cell-derived cardiomyocytes and rat neonatal cardiac cells. J Mol Cell Cardiol, 46, 213-224.
40. Sharif S, Mirzadeh H, Imani M, Rong Z, Jamshidi A, Shokrgozar M, Atai M, Roohpour N. (2009). Injectable in situ forming drug delivery system based on poly(epsilon-caprolactone fumarate) for tamoxifen citrate delivery: Gelation characteristics, in vitro drug release and anti-cancer evaluation. Acta Biomater, 5, 1966-1978.
41. Sohn YS, Cho YH, Baek H, Jung O-S. (1995). Synthesis and properties of low molecular weight polyphosphazenes. Macromolecules, 28, 7566-7568.
42. Su J, Iomdina E, Tarutta E, Ward B, Song J, Wildsoet CF. (2009). Efects of poly(2-hydroxyethyl methacrylate) and poly(vinyl-pyrrolidone) hydrogel implants on myopic and normal chick sclera. Exp Eye Res, 88, 445-457.
43. Tang Y Singh J. (2009). Biodegradable and biocompatible thermosensitive polymer based injectable implant for controlled release of protein. Int J Pharm, 365, 34-43.
44. Tevaarwerk AJ, Holen KD, Alberti DB, Sidor C, Arnott J, Quon C, Wilding G, Liu G. (2009). Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies. Clin Cancer Res, 15, 1460-1465.
45. Wang SH, Shi X, Chen X, Baker JR Jr. (2009a). Terapeutic efcacy of 2-methoxyestradiol microcrystals encapsulated within polyelectrolyte multilayers. Macromol Biosci, 9, 429-436.
46. Wang T, Jiang XJ, Lin T, Ren S, Li XY, Zhang XZ, Tang QZ. (2009b). Te inhibition of postinfarct ventricle remodeling without polycythaemia following local sustained intramyocardial delivery of erythropoietin within a supramolecular hydrogel. Biomaterials, 30, 4161-4167.
47. Wang Y Lapitsky Y Kang CE, Shoichet MS. (2009c). Accelerated release of a sparingly soluble drug from an injectable hyaluronan-methylcellulose hydrogel. J Control Release, 140, 218-223.
48. Yang CY, Song B, Ao Y Nowak AP, Abelowitz RB, Korsak RA, Havton LA, Deming TJ, Sofroniew MV. (2009a). Biocompatibility of amphiphilic diblock copolypeptide hydrogels in the central nervous system. Biomaterials, 30, 2881-2898.
49. Yang Y Wang J, Zhang X, Lu W, Zhang Q. (2009b). A novel mixed micelle gel with thermo-sensitive property for the local delivery of docetaxel. J Controlled Release, 135, 175-182.
50. Zhu BT, Conney AH. (1998). Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res, 58, 2269-2277. (Pubitemid 28252677)